Northwind Pharmaceuticals reposted this
Northwind Pharmaceuticals clients are mitigating the financial impact of GLP-1s by offering them as part of our #ClinicalBlueprints - our high-touch, programmatic, approach to supporting members struggling with diabetes and obesity. Keeping GLP-1's off-plan avoids the challenge of manufacturer dictated limits on prior authorizations and step therapy - a true danger point for plans wanting the benefits of these drugs with appropriate guard rails to ensure they are used appropriately. Without programmatic controls, utilization of GLP-1's will continue to grow far past the patients for whom they are most appropriately prescribed. There are effective approaches to getting the most out of these powerful drugs while mitigating their economic impacts.
Employers Increasing Offering of GLP-1 Drugs According to a survey of global employers released by the International Foundation of Employee Benefit Plans: • About one-third of U.S. employer health plans are offering coverage of GLP-1 drugs for both diabetes management and weight loss, up from last year. • GLP-1 drugs for weight loss grew as a portion of employers' overall medical claims spending to 8.9% in 2024 from 6.9% in 2023. Only about 26% of employers offered the drugs last year. • Some 57% of employers surveyed cover the drug Read More: https://lnkd.in/gSkhsNim)